Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1976 1
1978 1
1991 1
1995 1
1996 1
1997 1
1998 2
1999 7
2000 3
2001 9
2002 3
2003 4
2004 4
2005 3
2006 7
2008 2
2009 3
2010 2
2011 5
2012 3
2013 10
2014 7
2015 9
2016 5
2017 6
2018 1
2019 2
2020 3
2021 2
2022 2
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

103 results

Results by year

Filters applied: . Clear all
Page 1
Sharing: prisoner--patient.
Steidl S. Steidl S. Nursing. 1978 Dec;8(12):120. doi: 10.1097/00152193-197812000-00022. Nursing. 1978. PMID: 251865 No abstract available.
Activity of tafasitamab in combination with rituximab in subtypes of aggressive lymphoma.
Patra-Kneuer M, Chang G, Xu W, Augsberger C, Grau M, Zapukhlyak M, Ilieva K, Landgraf K, Mangelberger-Eberl D, Yousefi K, Berning P, Kurz KS, Ott G, Klener P, Khandanpour C, Horna P, Schanzer J, Steidl S, Endell J, Heitmüller C, Lenz G. Patra-Kneuer M, et al. Among authors: steidl s. Front Immunol. 2023 Jul 31;14:1220558. doi: 10.3389/fimmu.2023.1220558. eCollection 2023. Front Immunol. 2023. PMID: 37600821 Free PMC article.
CD19 occupancy with tafasitamab increases therapeutic index of CART19 cell therapy and diminishes severity of CRS.
Sakemura RL, Manriquez Roman C, Horvei P, Siegler EL, Girsch JH, Sirpilla OL, Stewart CM, Yun K, Can I, Ogbodo EJ, Adada MM, Bezerra ED, Kankeu Fonkoua LA, Hefazi M, Ruff MW, Kimball BL, Mai LK, Huynh TN, Nevala WK, Ilieva K, Augsberger C, Patra-Kneuer M, Schanzer J, Endell J, Heitmüller C, Steidl S, Parikh SA, Ding W, Kay NE, Nowakowski GS, Kenderian SS. Sakemura RL, et al. Among authors: steidl s. Blood. 2024 Jan 18;143(3):258-271. doi: 10.1182/blood.2022018905. Blood. 2024. PMID: 37879074 Free PMC article.
Tafasitamab mediates killing of B-cell non-Hodgkin's lymphoma in combination with γδ T cell or allogeneic NK cell therapy.
Her JH, Pretscher D, Patra-Kneuer M, Schanzer J, Cho SY, Hwang YK, Hoeres T, Boxhammer R, Heitmueller C, Wilhelm M, Steidl S, Endell J. Her JH, et al. Among authors: steidl s. Cancer Immunol Immunother. 2022 Nov;71(11):2829-2836. doi: 10.1007/s00262-022-03165-w. Epub 2022 Mar 29. Cancer Immunol Immunother. 2022. PMID: 35348812 Free PMC article.
Serum urate and cardiovascular events in the DCCT/EDIC study.
Jenkins AJ, Braffett BH, Basu A, Bebu I, Dagogo-Jack S, Orchard TJ, Wallia A, Lopes-Virella MF, Garvey WT, Lachin JM, Lyons TJ; DCCT/EDIC Research Group. Jenkins AJ, et al. Sci Rep. 2021 Jul 9;11(1):14182. doi: 10.1038/s41598-021-90785-4. Sci Rep. 2021. PMID: 34244538 Free PMC article. Clinical Trial.
103 results